CAMPTO

This brand name is authorized in Cyprus, Estonia, France, Hong Kong SAR China, Israel, Japan, Malta, Nigeria, Poland, Singapore, South Africa, Tunisia, UK.

Active ingredients

The drug CAMPTO contains one active pharmaceutical ingredient (API):

1	Irinotecan UNII 042LAQ1IIS - IRINOTECAN HYDROCHLORIDE
	Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I.
	Read more about Irinotecan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAMPTO Concentrate for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CE02	Irinotecan	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CE Topoisomerase 1 (TOP1) inhibitors
Discover more medicines within L01CE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1033827, 1071087, 1330254
FR	Base de données publique des médicaments	60120812
GB	Medicines & Healthcare Products Regulatory Agency	155461, 46968, 80895
HK	Department of Health Drug Office	42884
IL	מִשְׂרַד הַבְּרִיאוּת	6136, 6137, 6471
JP	医薬品医療機器総合機構	4240404A1040, 4240404A2047
MT	Medicines Authority	MA505/04701, MA505/04702, MA505/04703
NG	Registered Drug Product Database	04-9873
PL	Rejestru Produktów Leczniczych	100079286, 100079292
SG	Health Sciences Authority	09428P
TN	Direction de la Pharmacie et du Médicament	10803013H, 10803014H, 10803015H
ZA	Health Products Regulatory Authority	31/26/0183, 43/26/1067